» Articles » PMID: 39505260

Deducing Formation Routes of Oxylipins by Quantitative Multiple Heart-cutting Achiral-chiral 2D-LC-MS

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2024 Nov 6
PMID 39505260
Authors
Affiliations
Soon will be listed here.
Abstract

Several oxylipins are regulators of inflammation. They are formed by enzymes such as lipoxygenases or cyclooxygenases, but also stereorandomly by autoxidation. Reversed-phase liquid chromatography-tandem-mass-spectrometry (LC-MS/MS) methods for oxylipin quantification do not separate enantiomers. Here, we combine sensitive and selective oxylipin analysis with chiral separation using two-dimensional (2D)-LC-MS/MS. By multiple heart-cutting, the oxylipin peaks are transferred onto a chiral column. 45 enantiomeric pairs of (di-)hydroxy-fatty acids are separated with full gradient elution within 1.80 min, yielding lower limits of quantification <1 pg on the column. Concentrations, as well as enantiomeric fractions of oxylipins, can be determined, even at low concentrations or at high enantiomeric excess of one isomer. The developed achiral-chiral multiple heart-cutting 2D-LC-MS/MS method offers unprecedented selectivity, enabling a better understanding of the formation routes of these lipid mediators. This is demonstrated by distinguishing the formation of hydroxy-fatty acids by (acetylated) cyclooxygenase-2 and radical-mediated autoxidation. Applying the method to human M2-like macrophages, we show that the so-called specialized pro-resolving mediators (SPM) 5,15-DiHEPE and 7,17-DiHDHA as well as 5,15-DiHETE were present as (S,S)-enantiomers, supporting their enzymatic formation. In contrast, at least eight isomers (including protectin DX but not neutroprotectin D1) of 10,17-DiHDHA are present in immune cells, indicating formation by autoxidation. In the human plasma of healthy individuals, none of these dihydroxy-fatty acids are present. However, we demonstrate that all four isomers quickly form via autoxidation if the samples are stored improperly. Dihydroxy-FA should only be reported as SPM, such as resolvin D5 or resolvin E4, if an enantioselective analysis as described here has been carried out.

Citing Articles

The Octadecanoids: Synthesis and Bioactivity of 18-Carbon Oxygenated Fatty Acids in Mammals, Bacteria, and Fungi.

Revol-Cavalier J, Quaranta A, Newman J, Brash A, Hamberg M, Wheelock C Chem Rev. 2024; 125(1):1-90.

PMID: 39680864 PMC: 11719350. DOI: 10.1021/acs.chemrev.3c00520.


An Optimized Ex Vivo n-3 PUFA Supplementation Strategy for Primary Human Macrophages Shows That DHA Suppresses Prostaglandin E2 Formation.

Kirchhoff R, Kampschulte N, Rothweiler C, Rohwer N, Weylandt K, Schebb N Mol Nutr Food Res. 2024; 69(1):e202400716.

PMID: 39676434 PMC: 11704825. DOI: 10.1002/mnfr.202400716.


Chiral clues to lipid identity.

Das U, FitzGerald G J Lipid Res. 2024; 66(1):100710.

PMID: 39577773 PMC: 11699315. DOI: 10.1016/j.jlr.2024.100710.

References
1.
Stoll D, Shoykhet K, Petersson P, Buckenmaier S . Active Solvent Modulation: A Valve-Based Approach To Improve Separation Compatibility in Two-Dimensional Liquid Chromatography. Anal Chem. 2017; 89(17):9260-9267. DOI: 10.1021/acs.analchem.7b02046. View

2.
Mazaleuskaya L, Salamatipour A, Sarantopoulou D, Weng L, FitzGerald G, Blair I . Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res. 2018; 59(3):564-575. PMC: 5832923. DOI: 10.1194/jlr.D081414. View

3.
Pursch M, Buckenmaier S . Loop-based multiple heart-cutting two-dimensional liquid chromatography for target analysis in complex matrices. Anal Chem. 2015; 87(10):5310-7. DOI: 10.1021/acs.analchem.5b00492. View

4.
Ikei K, Yeung J, Apopa P, Ceja J, Vesci J, Holman T . Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation. J Lipid Res. 2012; 53(12):2546-59. PMC: 3494251. DOI: 10.1194/jlr.M026385. View

5.
Schebb N, Kuhn H, Kahnt A, Rund K, ODonnell V, Flamand N . Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators-What is the Evidence so far?. Front Pharmacol. 2022; 13:838782. PMC: 8924552. DOI: 10.3389/fphar.2022.838782. View